Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush

Kura Oncology (NASDAQ:KURA) had its target price hoisted by Wedbush from $34.00 to $36.00 in a research report released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. HC Wainwright increased their price objective on Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. UBS Group initiated coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Stock Down 2.5 %

Shares of KURA stock opened at $8.82 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The business has a 50-day moving average of $8.79 and a 200 day moving average of $15.11. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the previous year, the company earned ($0.50) earnings per share. On average, equities analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,255 shares of company stock valued at $100,739 in the last three months. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. nVerses Capital LLC bought a new position in Kura Oncology in the 3rd quarter worth about $25,000. Point72 DIFC Ltd bought a new stake in Kura Oncology during the 3rd quarter valued at about $146,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the fourth quarter worth about $90,000. Erste Asset Management GmbH bought a new position in shares of Kura Oncology in the third quarter worth approximately $215,000. Finally, Bellevue Group AG grew its holdings in shares of Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.